202-CoV low antigen dose

BIOLOGICAL2 trials

Sponsors

Shanghai Zerun Biotechnology Co.,Ltd

Conditions

COVID-19

Phase 1

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Shanghai Zerun Biotechnology Co.,LtdCOVID-19

Start: 2021-07-12End: 2023-06-30Updated: 2023-04-19

Phase 2

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Shanghai Zerun Biotechnology Co.,LtdCOVID-19

Start: 2021-07-31End: 2023-11-30Updated: 2023-04-19

Related Papers

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.

2022-12-161 citations

Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.

2021-10-3026 citations